NCT03614195

Brief Summary

The objective of this study is to investigate psychometric properties of dual-task walking assessments and compare effects of three types of dual-task balance interventions on dual-task walking for stroke patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Oct 2018

Typical duration for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 3, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

October 24, 2018

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

August 2, 2022

Status Verified

July 1, 2022

Enrollment Period

3.2 years

First QC Date

July 31, 2018

Last Update Submit

July 31, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • gait speed

    Participants will walk 10m at their preferred speed and at fast speed. A 12-meter walkway will be used for walking testing. In order to allow the subjects to have enough distance to accelerate and decelerate, only the time taken to walk the middle 10 meters will be recorded by a stopwatch. The primary gait parameter is gait speed (cm/s) under dual-task walking conditions using the 10 Meter Walking Test.

    10 minutes

  • composite score

    For all the cognitive tasks, we will calculate a composite score for cognitive-task performance by dividing the accuracy (% correct responses) with the reaction time of correct answers (milliseconds), which accounts for speed-accuracy tradeoffs in the overall dual-task effect.

    10 minutes

Secondary Outcomes (8)

  • Berg Balance Scale (BBS).

    5-10 minutes

  • Mini-Balance Evaluation Systems Test (Mini-BESTest).

    10 minutes

  • Timed Up and Go Test (TUG)

    2 minutes

  • Functional Gait Assessment (FGA).

    10 minutes

  • Activity-specific Balance Confidence Scale (ABC).

    2 minutes

  • +3 more secondary outcomes

Study Arms (3)

MCDTT

EXPERIMENTAL

The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.

Device: MCDTT

MDTT

ACTIVE COMPARATOR

The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.

Device: MDTT

CDTT

ACTIVE COMPARATOR

The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.

Device: CDTT

Interventions

MCDTTDEVICE

The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.

MCDTT
MDTTDEVICE

The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.

MDTT
CDTTDEVICE

The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.

CDTT

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) first-ever stroke with onset duration more than 3 months
  • (2) able to walk 10 m
  • (3) no severe vision, hearing, and language problems.

You may not qualify if:

  • orthopedic and other neurological disorders that affect walking
  • other treatments that could influence the effects of the interventions (e.g., recent Botulin toxin treatment of the lower extremity)
  • moderate or severe cognitive impairments (score \< 24 on Mini-Mental State Examination)
  • severe uncorrected visual deficits.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung University

Taoyuan District, 333, Taiwan

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 31, 2018

First Posted

August 3, 2018

Study Start

October 24, 2018

Primary Completion

December 31, 2021

Study Completion

December 31, 2021

Last Updated

August 2, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations